We report the anticarcinogenic, anti-aging polyphenol resveratrol activates the radio-and chemo-inducible cancer gene therapy vector Ad.Egr.TNF, a replication-deficient adenovirus that expresses human tumor necrosis factor a (TNF-a) under control of the Egr-1 promoter. Like ionizing radiation or chemotherapeutic agents previously shown to activate Ad.Egr.TNF, resveratrol also induces Egr-1 expression from its chromosomal locus with a possible role for Egr-1 promoter CC(A þ T)richGG sequences in the expression of TNF-a. Resveratrol induction of TNF-a in Ad.Egr.TNF-infected tumor xenografts demonstrated antitumor response in human and rat tumor models comparable to that of radio-or chemotherapy-induced TNF-a. Although sirtuins are known targets of resveratrol, in vitro inhibition of SIRT1 activity did not abrogate resveratrol induction of Egr-1 expression. This suggests that SIRT1 is not essential to mediate resveratrol induction of Egr-1. Nevertheless, control of transgene expression via resveratrol activation of Egr-1 may extend use of Ad.Egr.TNF to patients intolerant of radiation or cytotoxic therapy and offer a novel tool for development of other inducible gene therapies.
Introduction
The early growth response (Egr-1) gene promoter contains CArG (CC(A þ T)richGG) sequences. [1] [2] [3] Ionizing radiation (IR) as well as DNA-damaging chemotherapeutic agents readily induce the Egr-1 promoter via the CArG elements. [4] [5] [6] [7] This regulation is exploited in the replication-deficient adenoviral gene therapy vector Ad.Egr.TNF (TNFerade Biologic, GenVec Inc., Gaithersburg, MD), in which the pro-apoptotic cytokine tumor necrosis factor a (TNF-a), under control of CArG elements, is induced by radio-and/or chemotherapy. [5] [6] [7] [8] [9] This cancer gene therapy is currently in phase I, II and III trials and demonstrates synergistic antitumor effects with anticancer agents. 10, 11 However, not all cancer patients who might benefit from TNFerade can tolerate radiation and/or chemotherapy, suggesting that a nontoxic inducer of CArG elements may be clinically useful in some patients.
We report that resveratrol, an orally available, nontoxic compound, induces the Egr-1 promoter and drives production of TNF-a following treatment with Ad.Egr.TNF both in tumor cell lines in vitro and tumor xenografts in vivo. In vivo, treatment with resveratrol and Ad.Egr.TNF significantly inhibits tumor xenograft growth. These results may also be applicable to longterm gene therapy in patients with nonneoplastic disease where an orally available, nontoxic and nonmutagenic inducer of gene expression will have great value.
Methods
Cells and tissue culture MiaPaCa2, a human pancreatic adenocarcinoma cell line, DHD/K12/TRb (PROb), a rat colon adenocarcinoma established in syngeneic BD-IX rats by 1,2-dimethylhydrazine induction (obtained from Francois Martin, University of Dijon, France) and MCF-7, a human breast carcinoma cell line, were maintained in Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Carlsbad, CA) supplemented with fetal bovine serum (10% v/v, Serologicals Corp., Norcross, GA), penicillin (100 IU ml À1 ) and streptomycin (100 mg ml
À1
, Invitrogen Corp., Grand Island, NY) at 37 1C with 7.5% CO 2 .
Chemicals
Resveratrol was obtained from Cayman Corp. (Ann Arbor, MI). For all experiments, a 50 mg ml À1 stock solution in dimethyl sulfoxide (DMSO) was prepared and stored at À20 1C until use. SIRT1 inhibitor compounds Ex-527 and Ex-243 and the inactive compound Ex-242 were kind gifts from Dr Rory Curtis and Dr Julie Huber of Elixir Pharmaceuticals (Cambridge, MA). Ex-527 is a potent and SIRT1-selective small molecule inhibitor identified in a high-throughput screen using bacterially expressed human SIRT1. 12 Ex-243 is the active enantiomer purified from the racemic mixture Ex-527. Ex-242 is the purified inactive enantiomer, which serves as a control. The discovery and characterization of these compounds are described elsewhere. 13 For all experiments, a 10 mM stock solution of each compound in DMSO was prepared and stored at À80 1C until use.
Animals and viral vectors
Six-week-old female athymic nude mice (FCRI-Taconic, Germantown, NY) received food and water ad libitum. Experiments were in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of Chicago. Ad.Egr.TNF, a replication-deficient adenovirus constructed to express the human recombinant cytokine TNF-a under the control of the promoter of the Egr-1 gene (TNFerade Biologic, GenVec Inc., Gaithersburg, MD), was stored at À80 1C and diluted to the appropriate concentration in formulation buffer.
Western blot analysis of Egr-1 expression MiaPaCa2 and PROb cells were plated at 10 6 cells per plate in 60 mm 2 plates and grown overnight. Cells were serum starved for 12 h in the presence or absence of 10 mM SIRT1 inhibitor compounds Ex-527, Ex-243 and Ex-242, and then exposed to resveratrol (20 mg ml À1 ) in serum-free media. At hourly time points following resveratrol exposure from 1 to 6 h, cell lysates were harvested in the following manner: cells were washed once with phosphate-buffered saline (PBS) and harvested by scraping in 500 ml of cells lysis buffer (20 mM Tris at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 100 mM sodium orthovanadate, 1 mg ml À1 leupeptin, 1 mM phenylmethylsulphonylfluoride (PMSF)). Samples were then sonicated using a Branson Sonifier 450 (VWR Scientific, Danbury, CT) for 5 s and centrifuged at 14 000 r.p.m. to remove any cellular debris. Protein assays were carried out using Bio-Rad dye reagent (Bio-Rad Laboratories, Hercules, CA) to normalize protein concentrations. Equal amounts of protein were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to Immobilon (Fisher Scientific Company, Hanover Park, IL) and blocked with 5% nonfat dry milk in Tris-buffered saline (TBS)-Tween 20 (0.1% v/v) for 1 h at room temperature. The membranes were incubated overnight in primary antibody to Egr-1 (Santa Cruz Biotechnology, Santa Cruz, CA) or Actin (Santa Cruz Biotechnology) at dilution of 1:1000 in 5% bovine serum albumin in In vitro luciferase reporter assay The Egr-1 constructs pGL3 425 (596 bp containing all CArG elements and no AP-1 sites) and pGL3 660 (the minimal Egr-1 promoter of 115 bp containing no CArG elements) as previously described in Park et al. 5 were used to transfect MiaPaCa2 and PROb cells. MiaPaCa2 and PROb cells were plated at 10 5 cells per well in 12-well plates (Fisher Scientific Company) and transfected with the firefly luciferase reporter constructs-pGL3 basic (promoterless, negative control), pGL3 660 (minimal Egr-1 promoter) and pGL3 425 (Egr-1 containing all CArG elements)-using Superfect transfection reagent (Qiagen Inc., Valencia, CA). All groups were co-transfected with the Renilla luciferase construct pRL-TK (herpes simplex virus thymidine kinase promoter) to normalize transfection efficiency. At 24 h, cells were exposed to IR (5 Gy) or resveratrol (20 mg ml
À1
). Cells were harvested 24 h later, and luciferase activity was measured using a Dual-Luciferase reporter assay system (Promega Corp., Madison, WA).
In vitro measurement of TNF-a protein MiaPaCa2 and PROb cells were plated at 10 5 cells per well in 12-well plates grown overnight, and infected with Ad.Egr.TNF at the multiplicity of infection of 100 in serum-free media for 3 h. Cells in the IR group were exposed to 5 Gy radiation in complete media using a Gammacell 220 (MDS Nordion, Vancouver, British Columbia, Canada). Cells in the resveratrol group were exposed to 20 mg ml À1 in complete media. Cells and supernatants were harvested at 24, 48 and 72 h by scraping. Three freeze-thaw lysis cycles were carried out and the cells were then sonicated. Human TNF-a production was quantified using a Quantikine ELISA Kit (R&D Systems Inc., Minneapolis, MN). These experiments were carried out in triplicate. Duplicate treatments were carried out in 96-well plates using 2 Â 10 3 cells to adjust for the cytotoxicity of IR and resveratrol. Media was aspirated and changed to 100 ml of complete media and 20 ml of MTS reagent (Promega Corp.). After 2 h, measurements were taken at 450 nm wavelength with a Spectramax 340 plate reader (Molecular Devices Corp., Sunnyvale, CA). Data are expressed as mean±s.e.m. of experiments carried out in triplicate.
In vivo measurement of TNF-a protein MiaPaCa2 and PROb cells were injected at 5 Â 10 6 cells per 0.1 ml into the hindlimbs of athymic nude mice. Tumor-bearing mice with average tumor size of approximately 250 mm 3 were randomized into four groups: intratumoral injection (i.t.) of Ad.Egr.TNF (2 Â 10 8 plaque-forming units per 10 ml) with intraperitoneal (i.p.) injection of DMSO or resveratrol (20 mg kg À1 ) and i.p. DMSO or resveratrol treatment without Ad.Egr.TNF treatment. Two consecutive i.t. injections were given 24 h apart. DMSO (i.p.) or resveratrol treatments were given immediately following transfection with i.t. vector twice a day for 4 days. Animals were euthanized and xenografts were harvested 48 h after the second i.t. injection. Xenografts were snap frozen in liquid nitrogen and homogenized in radioimmuno precipitation assay buffer (150 mM NaCl, 10 mM Tris at pH 7.5, 5 mM EDTA pH 7.5, 100 mM PMSF, 1 mg ml À1 leupeptin and 2 mg ml À1 aprotinin) using a Brinkmann Polytron homogenizer (Kinematica AG, Lucerne, Switzerland). After three freeze-thaw lysis cycles, the homogenate was centrifuged at 7800g in a Sorvall SS34 rotor (Kendro Laboratory Products, Newton, CT) for 10 min at 4 1C. TNF-a levels in the supernatants were measured as described above.
In vivo regrowth studies MiaPaCa2 or PROb cells (5 Â 10 6 cells per 100 ml) were injected into the right hindlimb of athymic nude mice. Tumor-bearing mice were assigned into one of four groups: Ad.Egr.TNF (i.t., 2 Â 10 8 plaque-forming units per 10 ml) with DMSO (i.p.) or resveratrol (20 mg kg À1 ) or 
Statistical analysis
Statistical significance was determined using the twotailed Student's t-test.
Results and discussion
Resveratrol (trans-3,5,4 0 -trihydroxystilbene), a stilbene phytolexin found in grape skins and red wine, is a cancer chemopreventive, anti-inflammatory and antiaging polyphenol that has been shown to induce Egr-1 in several studies. [14] [15] [16] [17] [18] Resveratrol (20 mg ml
À1
) induced Egr-1 protein expression in two cancer lines: PROb rat colorectal and MiaPaCa2 human pancreatic cells, with peak induction occurring at 4 h and persisting at least 6 h post-treatment ( Figure 1a ). To study whether the CArG sequences of Egr-1 are required for resveratrol induction, both cell lines were co-transfected with the firefly luciferase reporters pGL3 660, a minimal Egr-1 promoter containing no CArG elements, or pGL3 425, an Egr-1 promoter containing all CArG elements but no AP-1 sites, along with the Renilla luciferase internal control reporter plasmid pRL-TK (thymidine kinase). Resveratrol failed to induce pGL3 660, but pGL3 425 luciferase expression was increased in PROb and MiaPaCa2 cells compared to the untreated control (Po0.019, Figures 1b and c) . These results demonstrate the CArG sequences may be necessary for resveratrol induction of Egr-1. However, a 350 bp of non-CArG DNA sequences are in the pGL3425 vector and may also be involved in Egr-1 induction. When MiaPaCa2 or PROb cells were infected with Ad.Egr.TNF and treated with resveratrol, TNF-a was induced well above baseline (Figures 2a and b) .
Recently, resveratrol and related polyphenols have been reported to extend the lifespan of Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila melanogaster purportedly through activation of sirtuins, a class of nicotinamide adenine dinucleotide-dependent histone deacetylases. 19, 20 SIRT1 is known to deacetylate p53. Acetylation stabilizes p53 by inhibiting ubiquitination and degradation. 21 Based on these data, we investigated whether resveratrol induction of Egr-1 potentially acts through SIRT1 activation. We employed a small molecule inhibitor of SIRT1, Ex-527, which consists of a racemic mixture of Ex-243, the active optical isomer and Ex-242, the inactive optical isomer, which serves as a control compound. SIRT1 inhibitors are not expected to alter the levels of SIRT1, but rather inhibit the deacetylase activity of SIRT1. To assay SIRT1 inhibition, we therefore examined potential changes in levels of acetylated-p53, a SIRT1 target, rather than SIRT1 expression itself. We confirmed SIRT1 inhibitory activity of these compounds by demonstrating enhanced ) compared with cells infected with vector alone (35 ± 5, 25 ± 7 and 19 ± 1 pg ml
; P ¼ 0.089, P ¼ 0.018 and Po0.001). Combined treatment with resveratrol and Ad.Egr.TNF resulted in 0.8-, 4.0-and 10.6-fold increases in TNF-a production over vector alone. IR was used as a positive control for induction of the vector. In MiaPaCa2 cells infected with Ad.Egr.TNF and exposed to IR (5 Gy), a similar induction was seen at 24, 48 and 72 h (43±11, 141 ± 19 and 61 ± 9 pg ml À1 ; P ¼ 0.511, P ¼ 0.004 and P ¼ 0.0011). Combined treatment with Ad.Egr.TNF and IR resulted in 1.2-, 5.6-and 3.2-fold increases in TNF-a production compared to vector alone. Data is reported as mean±s.e.m. (b) In PROb cell cultures treated with Ad.Egr.TNF and resveratrol increased levels of TNF-a were observed at 24, 48 and 72 h (18 ± 9, 112 ± 21 and 121 ± 27 pg ml À1 ) compared with cells infected with vector alone (0±0, 8±1 and 13±2 pg ml
; P ¼ 0.16, P ¼ 0.007 and P ¼ 0.015). Combined treatment with resveratrol and Ad.Egr.TNF resulted in 13.8-and 9.6-fold increases in TNF-a production at 48 and 72 h. PROb cells infected with Ad.Egr.TNF and exposed to IR (5 Gy) at 24, 48 and 72 h (9±5, 21 ± 1 and 27 ± 1 pg ml À1 ; P ¼ 0.132, Po0.001 and P ¼ 0.002).
p53 acetylation in the presence of Ex-527 and Ex-243, as compared with the inactive optical isomer Ex-242. (Figure 3 ) We demonstrate that in vitro inhibition of SIRT1 activity using these compounds did not abrogate resveratrol induction of Egr-1 expression in PROb cells (Figure 4) . Additionally, MiaPaCa2 expresses no SIRT1 Etoposide Figure 3 Assay of SIRT1 inhibition by Ex-527 and Ex-243 by immunoblot of p53 acetylation. It has been previously described that inhibition of SIRT1 catalytic activity enhances p53 lysine 382 acetylation after DNA-damaging agents. 13 In replicate wells, MCF-7 cells were treated with Ex-527, Ex-243 and the inactive enantiomer Ex-242 overnight for 12 h. In the continued presence of Ex-527, Ex-243 or Ex-242, cells were then exposed to the DNA-damaging agent etoposide to induce p53 acetylation for 6 h. Lysates were immunoblotted with an anti-acetyl p53 Lys-382 antibody or p53 antibody. p53 acetylation was enhanced in the presence of the potent and selective SIRT1 inhibitors Ex-527 and Ex-243 but not the control inactive enantiomer Ex-242. Total p53 levels act as a loading control. Acetylated p53 levels in PROb cells could not be examined due to lack of availability of a rat-specific acetyl-Lys382-p53 antibody. detectable by Western analysis (data not shown). These results demonstrate that SIRT1 is not essential for mediating resveratrol induction of Egr-1. The precise mechanism by which resveratrol induces Egr-1 promoter expression remains to be elucidated.
As a cytotoxic gene therapy model, we treated MiaPaCa2 and PROb tumor xenografts with Ad.Egr.TNF, resveratrol or the combination of each. Both cell types demonstrated marked TNF-a induction when treated with Ad.Egr.TNF and resveratrol versus either agent alone (Figures 5a and b) . Prior work in our laboratory has demonstrated that there is no induction of endogenous TNF-a production with treatment by a null adenoviral vector and agents that otherwise induce the adenoviral vector containing the Egr-1 promoter. 5, 6 The combined Ad.Egr.TNF/resveratrol treatment also reduced tumor growth substantially, compared to either agent alone (Figures 5c and d) . Previous work showed that Ad.Egr.TNF did not measurably increase toxicity of experimental radio-or chemotherapy. Here, no apparent toxicities or deaths occurred in tumor-bearing mice treated with resveratrol with or without Ad.Egr.TNF. Thus, Ad.Egr.TNF induction by resveratrol or other sirtuin activators might offer high intratumoral TNF levels without adverse effects as observed in patients treated with chemotherapy and TNFerade.
Importantly, the antitumor effects of combining resveratrol and Ad.Egr.TNF are equal to or greater than the previously reported combination effects of the chemotherapeutic agents cisplatin or doxorubicin with Ad.Egr.TNF. 5, 6 Contrary to our previous understanding, these findings suggest that the antitumor effects observed with TNFerade may be due to the cytotoxicity or other effects of TNF-a itself rather than enhancement of radiation or chemotherapy toxicity. Our findings extend the potential applications of a CArG inducible TNFbased gene therapy to patients' tumors where cytotoxins or radiation are either ineffective or poorly tolerated. For example, in prostate cancer, where radiotherapy and surgery are strongly associated with impotence, incontinence and rectal injury, 22 cytotoxic therapy via local infection with TNFerade and induction by resveratrol might offer an attractive alternative. More broadly, combining resveratrol with stable transduction of target tissues by CArG-dependent expression vectors might provide a practical answer to a current challenge for gene therapy. An orally available inducer might have particular value in other hormonal therapies, facilitating regulation of erythropoietin levels to maintain hematocrit, dynamic control of insulin in diabetes or pulsatile expression of growth hormone to restore growth and maturation in pituitary insufficiency.
